Candidates for the ETPN Executive Board 2023-2025
Discover the program & background of the candidates for the elections of the ETPN General Assembly 2023
UMC UtrechtCandidate CV
Raymond Schiffelers CV
Raymond Schiffelers studied Bio-Pharmaceutical Sciences at Leiden University (1990-1995). After an industrial traineeship at SmithKline Beecham Pharmaceuticals (UK) he did his PhD in medical microbiology at Erasmus University Rotterdam on liposomal targeting of antimicrobial agents (1996-2001). Subsequently he became post-doc at Utrecht University working on liposomes targeting tumor vasculature. In 2002-2003, at Intradigm Co (USA) he expanded his tumor vasculature-targeting work with polymers for delivery of siRNA. After his return to Utrecht University he became assistant and then associate professor. He received an ERC Consolidator Grant in 2010 to investigate extracellular vesicles as biological drug delivery systems. After he moved to University Medical Center Utrecht in 2011 he became professor of nanomedicine working on bio-inspired and synthetic drug delivery systems. He coordinates two H2020 projects on this topic, B-SMART and EXPERT, and one HEurope project NANO-ENGINE. He is also coordinator of a project of the Netherlands Science Agenda Nanospresso-NL aiming to make bedside production of nucleic acid nanomedicines a reality. He is editor for the International Journal of Pharmaceutics, Journal of Controlled Release and Journal of Extracellular Vesicles, and is founder of EXCYTEX-an extracellular vesicle-based company. Since 2021 he also works part-time for Nanocell Therapeutics as VP Preclinical R&D.
Raymond Schiffelers Programme
The past two years, the Executive Board Team has been focused on the consolidation of the ETPN Association. Making sure we have stable finances for the foreseeable future, modernizing our banking system and human resources management and positioning ourselves within the changed R&D environment of Horizon Europe.
On behalf of the majority of the past Executive Board of the ETPN Association, I have the honor and the great pleasure to call for your renewed support for the next two years.
We will continue the best liked activities of ETPN:
- brokerage sessions, to pitch your proposal, to find partners and to learn what can be read in the call texts between the lines.
- webinars for a quick update on a topic
- further expand content collection, with presentations, posters, and webinars
- continuation of the HealthTechTAB, offering customized mentoring to bring your invention to fruition
We are also totally renewing the ETPN membership experience. You are now able to showcase your institution, to highlight services, propose collaborations, and highlight key infrastructure and people. In parallel, we launch the new Nanomed Map 2.0 where ETPN members will be highlighted among all Nanotech stakeholders. We’ve worked hard to make these new features very useful and enjoyable to use for you.
On our priority list for the next years:
- Increase participation of ETPN in Horizon Europe (and other funding organizations') nanomedicine projects. Our unique experience in stakeholder management, communication and exploitation can give your project a unique edge to cross the cut-off fr funding
- Reorganize the Working Groups structure to reflect the maturity of the field with special emphasis on Regulatory aspects
- Develop curated Nanomedicine Academy content
- Further develop our position in the European R&D space (e.g. through our recently acquired ERA4Health Strategic Advisory Board membership)
I hope we can count on your support
ETPN Vice Chairperson
(2 open positions)
Gesellschaft für Bioanalytik Münster e.V.Candidate CV
Kathleen Spring CV
Kathleen Spring, PhD, managing director at Gesellschaft für Bioanalytik Münster e.V. in Münster, Germany. Bioanalytik Münster is a is a non-profit organisation. It’s a regional network which was initiated in 2000 by local universities, research centres, enterprises, transfer institutions and investors to promote science, research and education in the field of (nano) bioanalytics in Münster region. We provide a central communication and information platform for scientists, entrepreneurs, investors and members of the public who are interested in bioanalytics. Bioanalytik Münster was involved as a partner in several EU-funded projects over the past 15 years always being a reliable strategic partner. The H2020 project REFINE was coordinated by Bioanalytics Muenster and was initiated by the nanomedicine community, helping them to prepare products for regulation and on the other hand to create a regulatory science framework for the risk-benefit assessment of nanomedical products.
I hold a Diploma in Human Biology of the University of Greifswald (2007) and a PhD (2012) in Molecular Biology of the University of Montreal, Canada. Since 2017 I worked for Bioanalytik Münster, since 2020 as Managing Director. Since 2017 I am also a member of ETPN participating since 2019 actively supporting the board. I have experience in science and research as well as in organisation and managing.
Kathleen Spring Programme
I would like to apply for the vice president position of ETPN. I take part of the Team Ray Schiffler (Team RS) and I strongly support the common goals of his team (see application Ray Schiffler) for the coming two years of ETPN. The team would appreciate to be elected as a team.
The future ETPN should continue to be the think tank and the ambassador for the nanomedicine community in Europe. ETPN contributed to some successful proposals in the new (EC) Horizon Europe (HEU) which showed that we reached our goal of our last election period: embracing the vision that the ETPN strives to adress unmet healthcare needs with innovative nanotechnology-based solutions for the benefit of patients. We will continue to address the vision of ETPN in the upcoming years and support its role as a broker between different partners and to make matches between different expertise to make the best consortia possible. In addition, ETPN has changed a lot its internal work organisation and financial management to be even more efficient and offer the best services to members.
For the next period 2023-2025, we want to restructure the working groups to a more task force like acting structure to be more agile and interactive including also young researchers in the strategic work in different topics. We aim to strengthen the role of ETPN as an ambassador of the nanomedicine community, to be their voice when representing the nanomedicine community in Europe’s innovation ecosystem.
In line with these ideas, I would like to participate shaping the future vision of ETPN and to contribute implementing these ideas. I see the role of the vice president in the support, distribution, continuous development and evolution of the goals of ETPN in the next two years. I am happy to support the ETPN and his board where needed.
Professor Steven Conlan
Swansea UniversityCandidate CV
Professor Steven Conlan CV
- Professor of Molecular and Cell Biology, Swansea University Jan 2000 -
- Fellow of the Royal Society of Biology (FRSB).
- Member and Trustee British Society of NanoMedicine
- 2022- Chief Scientific Officer, Continuum Life Sciences Ltd.
- 2021- Co-Vice Chair European Technology Platform Nanomedicine.
- 2020- Chair and Trustee British Society of NanoMedicine.
- 2019- Research and Innovation lead and Programme Board, Genome Partnership Wales.
- 2019- Research and Innovation lead and Programme Board, Advanced Therapies Wales.
- 2019- Executive Board, Wales Cancer Research Centre.
- 2019- Pathology Strategy Development Group, Swansea Bay University Health Board
- Full Affiliate Member, Houston Methodist Research Institute, Houston, Texas.
- Honorary Consultant, Swansea Bay University Health Board.
- PhD Molecular Biology, University of London (Wye College), 1994.
- Biology BSc (Hons), University College Swansea, 1989.
Professor Steven Conlan Programme
As incumbent ETPN Co - Vice Chairperson it has been an exciting two years working as an ExBo member, contributing to the continued success of ETPN. Over this period we have run an online seminar series focused around ETPN working groups that have seen great attendance, and give a wider outreach to the platform. I will push to see these continue and expand. We have had a growth in our membership across our sector including from industry and academia, I think we on an upward trajectory, and will work together with my ExBo colleagues to continue this important aspect of ETPN which is growing our European network, and delivering impact for our members. Key to my joining the ExBo was to see the UK and EU continue to work closely through the ETPN. With the Windsor accord, and the UK and EU governments in negotiations about association of the UK to Horizon Europe which is hoped will be successful, I think a positive outcome will bolster pan-Europe opportunities for the ETPN and its members. Excitingly, ETPN is co-hosting, along with the British Society for Nanomedicine (where I am Chairperson) and the University of Liverpool the NME2023 conference. It is exciting to see this come to fruition, and I look forward to meeting many of our members and colleagues soon, where we will celebrate the continued growth and importance of nanomedicine in health and wellbeing.
Dr. Alexandre Superville
Jedha Bootcamp / Former project manager at the ETPNCandidate CV
Dr. Alexandre Superville CV
Administration & finance manager
13 years professional experience
Administrative & financial management (France) / Private company – Association – Public administration – European project
Scientist & project manager / Research project – Institutional, scientific & corporate communication – Life sciences PhD + MBA
Partner & CFO – Jedha (Paris, Lyon, France) - Partner 01/2020 – today ; CFO 09/2020 – today
Re-organisation & direction of the administrative & financial department. Jedha is a data science & cybersecurity training start-up (www.Jedha.co).
Project Manager – ETP-Nanomedicine (Paris, France)
04/2018 – 12/2020 (2,5 years)
Management of the H2020 CSA NOBEL (8 Partners, structuration of the European HealthTech community, www.nobel-project.eu)
Support in the ETPN financial management (association under French law)
Scientific cooperation task officer – French Embassy in Israel (Tel-Aviv, Israel)
09/2015 – 09/2017 (2 years)
Improvement of Franco-Israel scientific cooperation, notably through cooperative research funding management, scientific communication & event organisation
R & D - Physiopathology
- PhD student – ICAN Institute, UPMC / INSERM (Paris, France)
- Intern – The University of Cambridge (UK)
03/2010 - 09/2014 (4,5 years)
Research activities on atherosclerosis (PhD) & fatty-liver disease (Internship). PhD thesis defence & publication : New insights in signalling pathways controlling lipid homeostasis and inflammation in human macrophages during atherosclerosis (www.theses.fr/2014PA066496)
PhD - Physiology and physiopathology, Université Paris 6, 4 years, 2014
MBA, Collège des Ingénieurs, 15 weeks, 2015
Data Science - Essentials, Jedha Bootcamp, 40 hours, 2019
Dr. Alexandre Superville Programme
Dear ETPN Members,
I hope this message finds you well. Today, I am humbly declaring my intent to seek re-election as Treasurer of the European Technology Platform on Nanomedicine (ETPN) for the term of 2023-2025.
During my previous term, we have made significant strides in fortifying our financial processes, ensuring the sustainability of ETPN, and, most importantly, enhancing value for our members. Our members continue to be at the heart of our operations and the key to our independence.
Looking ahead, we are presented with the unique opportunity - and challenge - of managing two major European projects concurrently, MetrINo and Nanospresso NL. This will be our first time managing multiple initiatives simultaneously, a challenge that I am ready to meet head-on with your support.
In the upcoming term, my focus will be on:
- Member Value: I will strive to ensure the most efficient use of membership fees, with the goal of providing our members with the best value possible, making this our top priority.
- Enhanced Process Management: I will refine our financial and administrative processes further, enabling smooth management of multiple projects.
- Financial Sustainability: I will work diligently to solidify the financial stability of ETPN, particularly within the Secretariat and our project portfolio.
- Membership Growth: I am committed to expanding our membership base, which will enrich our network and strengthen our financial stability.
I am prepared to work closely with the Board and the Secretariat to increase and diversify ETPN's funding sources, keeping transparency, and delivering maximum value to our members at the forefront of our endeavors.
Your trust and support in the previous term have brought us to this point, and I am enthusiastic to continue serving the ETPN community. I am confident that my proposed strategy aligns with your vision as an ETPN member, and I eagerly look forward to your support in the upcoming election.
prof Giovanni Tosi
University of Modena and Reggio EmiliaCandidate CV
prof Giovanni Tosi CV
Since November 2005, Dr. Giovanni Tosi is researcher in the scientific field of Pharmaceutical Technology at the University of Modena and Reggio Emilia (PI at the department of Pharmaceutical Sciences, which belongs to the faculty of Pharmacy). Since 2015, he is associate professor in the same field. He got certificate for Full professor in 2017, and now he is full Professor since 2020.
He was born in 1977 (March, 2nd) in Bologna, Italy, and got his degree in Pharmacy in 2002 with 110/110. He got his PhD in Pharmaceutical Sciences in 2005 at the University of Modena and Reggio Emilia, Italy. He was Coordinator of "Applied Technology" curricula for the PhD school in Health Products, member of Instruments Commission of Dep.Pharm.Sci., Contact Person ILO of Dep.Pharm.Sci, Research products, Representative of the Dep.Pharm.Sci. in the Central Board of Animal House and Committee for Research of University of Modena and Reggio Emilia. He now director of Hospital Pharmacy Specialization Programme and coordinator of KETs National Center for RNA drugs in Rare Diseases Spoke.
He is scientific delegate for international cooperation and coordinator of UNIMORE Nanomedicine Platform since 2017 and vice-chair of WG Nanotherapeutics in European Technology Platform for Nanomedicine since 2019 and now secretary of ETPN.
The research activity is based on the development of lipid and polymeric systems for the delivery and the targeting of drugs to diseased tissues or cells.
His works on nanomedicine for drug and gene delivery and targeting were honored with national prices and awards (La Manna Prize for Student Thesis he drived), Jorge Heller Oustanding Paper Award, 2005) and Innovation price (AFI2005, AFI 2006). His work on Nanoparticles for CNS drug delivery has been recently awarded as one of the Hot Topic (150 selected research over 19.000 proposals) at the World Neuroscience Meeting (Society for Neuroscience) in Washington DC, November 2011 and World Neuroscience Meeting (Society for Neuroscience) in New Orleans, November 2012.
He is author or co-author of more than 100 publications in international journals and gave over 200 presentations (invited speaker, oral presentations and posters) in international and national congresses.
He participated as collaborator or project leader in several Italian and International projects supported by the Italian Research Ministry, IMI project, Euronanomed grant, Ministry of International Cooperation Projects and POR FESR project. He is now collaborating with a broad network of scientists in the field confirmed by the international participation to publications and many national and international industries (Chiesi, Pfizer, Sanofi, Gilead Sciences, Biomarin). He currently acts as referee for the top journals in nanotechnology and nanomedicine such as Journal of Controlled Release, Biomaterial, Nanomedicine and many other journals dealing with Nanotechnology, Drug Delivery and Nanomedicine.He is Member of the Editorial Advisory Board of a number of
Last 5 years projects
- 2017-2022 Telethon grant: Targeting neurons with cholesterol. How can it change the future of Huntington Disease patients
- 2017- 2022 Cariparo Grant Paedriatic research: Pediatric neurodegenerative disorders: optimizing nanoparticle-mediated strategy for brain treatment.
- 2018-2023 IMI EU Grants: Investigating Mechanisms and Models predictive of accessibility of therapeutics (IM2PACT) Into the Brain.
- 2019-2023 PROGETTI DI RICERCA SCIENTIFICA E TECNOLOGICA DI GRANDE RILEVANZA, Ministero degli Esteri, Progetti Italy-USA, Nanomedicine for BBB-crossing in CNS oncologic pathologies.
- 2019-2022 Progetti PORFERS: Mat2Rep, Multifunctional Biomaterials for Regeneration in Traumatic Brain Injury
- 2020-2023 EuroNanoMed Grant: Silk-fibroin interventional nano-trap for the treatment of glioblastoma.
- 2020-2023 Vinci PhD Grant on Nanomed for Glioblastoma Treatment
- 2021-2023 -Creutzfeldt-Jakob Disease Foundation: Optimization of nanoparticle-mediated brain delivery of a tetracationic porphyrin with potent anti-prion activities
- 2022-2025: CN3 Centro Nazionale, National Center for Gene Therapy and Drugs based on RNA Technology, Spoke 1, Genetic Diseases
- 2022-2025: CN3 Centro Nazionale, National Center for Gene Therapy and Drugs based on RNA Technology, Spoke 2, Cancer
- 2022-2025: Health Extended ALliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine - HEAL ITALIA, Spoke 6, Development of innovative devices for precision diagnosis and personalized therapy
prof Giovanni Tosi Programme
My personal effort in ETPN community has been and will be dedicated to integration and support to all activities aimed to improve the large multidisciplinarity, which is, as all we know, so complex but at the same time so open to any kind of innovation.
I will be therefore ready for continuing the work we are currently developing together in ExBO lead by Prof Raymond Schiffelers in which I'm currently acting as Secretary.
Being involved in student/PhD formation due to my role in University, I do believe that the creation of the next generation of scientists working in research at different level will be fundamental and in particular in nanomedicine field will require the integration of skills and knowledge and ETPN community must be involved and it will be pivotal.
Regarding the next years for Nanomedicines, as all we know, the technological solutions used in the mRNA vaccinesdeveloped for the fight against Covid, the answer to these needs today is represented by the use of selective and targeted pharmaceutical delivery systems based nanomedicines.
My personal believe is that in the face of a consolidated readouts, however, in some research settings, multilevel difficulties are still present in the development of NMeds, both for large-scale production and in the availability of a fast and effective flow of certified analysis data that accompany the formulation development, able to provide adequate responses to requests deriving from the regulatory environment.
The misalignment that exists today in the research flow and the still unfilled gap between the production environment (in the laboratory as well as in a industrial setting) and analysis environment (from efficacy and safety checks in vitro or in preclinical models), determine a great expenditure of time, scientific and intellectual resources, as well as economic.
I do believe that in particular in the field of therapeutic proteins and their selective delivery through NMed, we could have the opportunity of building a network of laboratories capable of ensuring a quality path of design, production and characterization of delivery systems, and laboratories that guarantee an in vitro and in vivo validation system of the results obtained therefore represents an added value in the context of strengthening the laboratories of the region and the specific industrial fabric, but also in relation to the commitment of national and international pharmaceutical industry in the sector.
I believe that we can think to an operational network of laboratories with different backgrounds, but focused on the same objective would also be extremely attractive at a international level, thus making it possible to fill at least in part the dispersion mentioned above, and above all by providing interested companies with a clear and defined reference on which base the industrial advances necessary for commercialization and the clinical use of innovative strategies, creating a strong link between academia, scientific community, industrial setting and clinical setting.
Hoping in being part of the next effort in nanomedicine all together,
WG Medical devices Chairperson
Dr Lorena Diéguez
INL- International Iberian Nanotechnology Laboratory / RUBYnanomedCandidate CV
Dr Lorena Diéguez CV
Lorena Diéguez is the leader of the Medical Devices research group at INL. Her research is dedicated to Translational Medical Research in close collaboration with hospitals and focuses on the development of solutions based on microfluidics, biosensors and nanotechnology towards early diagnosis and better understanding of diseases. She is also very interested in translating her technology from the lab to the clinic and is co-founder and CEO of the spin-off company RUBYnanomed in the field of liquid biopsy. In RUBYnanomed, her role is to bring to market a new tool for patient monitoring and therapy selection in metastatic breast cancer. Between 2020 and 2021, she was part of the coordination team of INL’s Precise Personalised HealthTech cluster. Also, since 2019 and to date, she is the Chair of the Working Group in Medical Devices at the ETPN (European Technology Platform in Nanomedicine).
She obtained her Bachelors in Physics with Major in Optoelectronics at the University of Santiago de Compostela in 2005, then completed her Masters in Nanotechnology at the University of Barcelona (UB) in 2007 and her PhD in biosensors at the UB, the Institute for Bioengineering of Catalonia and the ETH Zürich. Her postdoc at the University of South Australia (2010-2013) was devoted to the study of rare cells from biological samples using microfluidics. Lorena joined INL in 2014 as Staff Researcher, before being promoted to Research Group Leader in 2018.
Lorena has published over 43 peer-reviewed research articles and reviews, 2 book chapters, has over 900 citations and an h-index of 18. She has participated in 26 national and international research projects, 17 of them as PI, and 6 of them as coordinator. She has also authored 5 patents, and been invited, keynote or plenary speaker in over 30 international conferences. She has also been recipient of several international research and innovation awards.
Dr Lorena Diéguez Programme
As with any voluntary work, my dedication to the ETPN is very limited. Still, over the last 4 years, I have done my best to contribute to all actions that the Executive Board jointly decided to undertake. As such, I was involved in surveys/consultations, whitepapers, webinars, brokerage sessions, and organization of ETPN annual meetings and NME conferences.
I believe the last years were full of changes with the transition from H2020 to HEU, with the launch of IHI, and the creation of the Health4EU Alliance. Those were even more relevant for the Medical Devices community.
And following these changes, the ETPN also has to adapt. My personal view is that the Working Group format of ETPN organisation is obsolete. As such, I have proposed for us to work on a new format, dedicated to building an strategic program 23-24 and horizontal task forces.
Some of those Strategic Priorities for 23-24 should be:
- Strengthen the relationship between EIC and the TAB
- Reinforce private-public partnerships for the MedTech sector in EU
- Promote connection of members with industry
- Focus on regulatory challenges
- Urging more EU funding for basic and translational research in nanomedicine and nanotech-enabled medical devices.
I really enjoy collaborating with ETPN through the ExBo, but I cannot promise I will increase my dedication to the ETPN. However, if the members believe that my input to the ExBo is positive, with my experience in research and entrepreneurship, I will be glad to continue and be part of the change of the EPTN operations for the next 2 years.
WG Regenerative Medicine Chairperson
WG Safety & Characterization Chairperson
Dr Neill Liptrott
The University of LiverpoolCandidate CV
Dr Neill Liptrott Programme
Having been involved with ETPN partners for nearly 10 years, and recently leading the successful application of the University of Liverpool (UoL) to ETPN, I am very keen to apply to chair the working group on safety and characterisation. My background is highly relevant to the working group as my research in the immunocompatibility of advanced therapeutics and complex medicines, such as nanomedicines, has supported the development of a number of these therapeutics through to clinical trials, as well as supporting industry stakeholders in the preclinical evaluation of their nanomedicines.
Related to nano-safety, I have a leading role in several international infrastructures, linking the safety and characterisation of nanomedicines. In 2015, UoL was instrumental in establishing the European Nanomedicine Characterisation Laboratory (EUNCL, Liptrott lead for Immunotoxicology) and subsequently, the REFINE project, where we developed a number of assays to move towards international standardisation of nanomedicine safety characterisation. More recently, our work has been to support the test case studies in the SAFE-N-MEDTECH OITB, in a number of work packages. At a national (UK) level, we have recently launched the £10 million Intracellular Drug Delivery Centre (IDDC), a national centre of excellence for developing and studying nanomedicines for nucleic acid delivery. Harmonisation of, relevant, safety and characterisation profiles are at the core of all that we do, and this has been recognised recently by my new role as Academic in Residence at the National Measurement Laboratory, in the UK, advising metrologists in the biological relevance of new representative materials and physicochemical characterisation.
I would be honoured to chair the working group and work with you all to enhance and promote cross-working group discussions and engagement, to support the nanomedicine community. A coherent, and robust, understanding of the safety profiles of these complex medicines is critical to their development, using a “safe-by-design” approach however, it is vital that this is accomplished in collaboration with relevant regulatory bodies to not only inform them of current trends and issues in the field but also to ensure that stakeholders have an efficient and relevant pathway to clinical development and application. Over the next 2 years, I will work to develop these cross-working group discussions to ensure that we can, further realise the potential of these complex medicines.
WG Clinical Translation Chairperson
Dr. PhD Marzia Bedoni
Fondazione Don GnocchiCandidate CV
Dr. PhD Marzia Bedoni CV
Dr. Marzia Bedoni (MB), female, born 10/07/1977 at Milan, is senior scientist and Head of Laboratory of Nanomedicine and Clinical Biophotonics (LABION: www.labion.eu) in FDG since 2018.
MB graduated in Biological Sciences at the University of Milan where she obtained also her PhD in Morphological Sciences (2007). She carried out her Post-Doc in FDG granted by the Cariplo Foundation, Seed Capital and FP7 call and became permanent researcher in 2011.
MB is expert in several fields of research: i) biophotonics application for diagnosis and therapy monitoring in neurodegenerative diseases (AD, ALS, PD), respiratory diseases like COPD, Asthma and SARS- CoV2; ii) nano-biophotonics for the characterisation of extracellular vesicles as diagnostic and regenerative rehabilitation markers; iii) nanoparticles for brain disease therapy like AD and glioblastoma.
She is member of the Leadership Council of the International Consortium for Regenerative Rehabilitation (founded by University of Pittsburgh, Stanford University and Mayo Clinic), Chair of the Clinical Translation and Social Impact Group in the European Technology Platform of Nanomedicine and Founding Member of Italian Society for Extracellular Vescicle (EVITA). Vice- President of Professional Association of Biology in Lombardy Region (Italy).
MB is also member and past board-member (2012-2017) of Society for Cutaneous Ultrastructure Research, member of European Society for Dermatological Research and Società Italiana di Anatomia e Istologia.
MB is Adjunct Prof Human Anatomy, Adjunct Prof Physiology, Adjunct Prof Epidemiology for University of Milan (since 2010). She is supervisor of PhD candidates of University of Milan, University of Brescia and University of Modena and Reggio Emilia and several undergraduates.
Principal Investigator of several national and international projects as recently:
-Call for collaborative projects II, Fondazione Regionale per la Ricerca Biomedica (2020-2023), " New frontiers of engineered nanovectors to improve treatment efficacy and safety in neurological disorders"(3.5 milion €)
- Co-PI of an European Project, Call EraPerMed 21 (2022-2025) " Raman analysis of saliva from COPD patients as new biomarker: AI-based point-of-care for the disease monitoring and management" (750.000 €)
MB is author of several peer-reviewed scientific papers and she is co-inventor of 5 patents on diagnosis device, diagnostic method and on transdermal therapeutic device. H index:23, Citation Index 1151. https://orcid.org/0000-0003-2618-3661
She received several awards during international congresses for her studies.
WG Education & Training Chairperson
PhD Monopoli Marco
PhD Monopoli Marco CV
2017- to date. Senior Lecturer (tenured) in the Chemistry Department of RCSI, Dublin
2016. SFI industry fellowship/R&D at Ludger Ltd, Oxfordshire, UK2009-2015. Junior to Senior Post doctoral fellow at the CBNI, UCD, Dublin
2004-2009. PhD in Pharmacology
Research output. Over 60 peer review articles, over 11,000 citations, H index: 34
PhD Monopoli Marco Programme
I have been involved with the WG of Education and Training since 2019 where I have worked closely with Georgina Kaklamani (FORTH, Greece) to support the WG Leader Education and Training Jack Barokas (TAU, Israel). In the past four years, we have worked closely with the ETPN secretary to set up a YouTube channel and an integrated platform in the ETPN website that has centralised and organised relevant content in nanomedicine. We have successfully uploaded 200 videos that are accessible by ETPN members only and forums for discussions.
I would be honoured to become the new chairperson of Education and Training, build on the work started by Jack, Georgina and me in the past years, and work together with anybody that would like to be involved.
In the next two years, I am planning to:
WP E&T intranet platform:
- Continue having the WG E&T platform and update it with relevant content provided by the ETPN members and WG leaders.
- Launch a blog function into the platform to encourage discussion and engagement between members of the ETPN.
- Create new topics for discussion in the ETPN intranet.
Launch of the ETPN academy
Our community is increasing and holds impressive knowledge in different aspects of nanomedicine and experienced lecturers. It is my ambition to launch the first ETPN academy for young researchers based on interactive sessions and active learning to up-skill the students’ knowledge and facilitate the building of their network in Europe.
WG Imaging ChairpersonNo candidates for this position.
WG Business Opportunities ChairpersonNo candidates for this position.
AG Ethics, Social Impact, Public Awareness ChairpersonNo candidates for this position.